OncoMatch/Clinical Trials/NCT06768489
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Is NCT06768489 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JNJ-79635322 and Daratumumab for multiple myeloma.
Treatment: JNJ-79635322 · Daratumumab · Pomalidomide · Lenalidomide — The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: targeted therapy
Targeted therapy ... within 21 days or 5 half-lives, whichever is less
Cannot have received: epigenetic therapy
epigenetic therapy ... within 21 days or 5 half-lives, whichever is less
Cannot have received: monoclonal antibody
monoclonal antibody (mAb) treatment ... within 21 days or 5 half-lives, whichever is less
Cannot have received: investigational drug
treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less
Cannot have received: gene-modified adoptive cell therapy
Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days
Cannot have received: anti-CD38 directed therapy
Exception: for treatment regimen A only: within 90 days; for regimen B: within 21 days
Prior anti-CD38 directed therapy within 90 days (for treatment regimen A only; within 21 days for treatment regimen B)
Cannot have received: conventional chemotherapy
Conventional chemotherapy within 21 days
Cannot have received: proteasome inhibitor
PI therapy within 14 days
Cannot have received: immunomodulatory agent
Immunomodulatory agent therapy within 7 days
Cannot have received: radiation therapy
Radiotherapy within 14 days
Cannot have received: allogeneic stem cell transplant
Allogeneic stem cell transplant within 6 months before the first dose of study treatment
Cannot have received: autologous stem cell transplant
Exception: received less than or equal to (<=)12 weeks before the first dose of study treatment
Received an autologous stem cell transplant less than or equal to (<=)12 weeks before the first dose of study treatment
Cannot have received: CD3-redirecting therapy
Prior treatment with CD3-redirecting therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06768489 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy, epigenetic therapy, monoclonal antibody disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages